Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer [Phase I and Clinical Pharmacology]

Conclusion
An LY2606368 dose of 105 mg/m2 once every 14 days is being evaluated as the recommended phase II dose in dose-expansion cohorts for patients with SCC.

Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Hong, Infante, Janku, Jones, Nguyen, Burris, Naing, Bauer, Piha-Paul, Johnson, Kurzrock, Golden, Hynes, Lin, Lin, Bendell Tags: Phase I and Clinical Pharmacology, Genitourinary, H&N, Lung, Other, Phase I and Clinical Pharmacology Source Type: research